Home > Annual Financials > VAISHALI PHARMA

VAISHALI PHARMA Financial Statement Analysis
[NSE : VAISHALI]

The Revenues of VAISHALI PHARMA have decreased by -8.12% YoY .
The Earnings Per Share (EPS) of VAISHALI PHARMA has decreased by -89.30 % YoY.
REVENUES
OPERATING MARGIN
PROFIT AFTER TAX
EPS
ROCE

VAISHALI PHARMA Last 5 Annual Financial Results
[NSE : VAISHALI]

StandaloneMar2024
Mar2023
Mar2022
Mar2021
Mar2020
Revenues ₹70 Cr₹76 Cr₹5,377,389 Cr₹60 Cr₹75 Cr
Expenses ₹60 Cr₹69 Cr₹5,112,586 Cr₹59 Cr₹73 Cr
Operating Profit (Excl OI) ₹9.38 Cr₹6.89 Cr₹264,803 Cr₹0.90 Cr₹2.08 Cr
Other Income ₹2.23 Cr₹1.79 Cr₹180,910 Cr₹2.17 Cr₹1.98 Cr
Interest ₹2.26 Cr₹2.49 Cr₹262,568 Cr₹2.56 Cr₹2.66 Cr
Depreciation ₹0.50 Cr₹0.46 Cr₹42,693 Cr₹0.44 Cr₹0.27 Cr
Profit Before Tax ₹8.85 Cr₹5.73 Cr₹140,452 Cr₹0.08 Cr₹1.13 Cr
Profit After Tax ₹6.60 Cr₹4.02 Cr₹104,626 Cr₹0.03 Cr₹0.71 Cr
Earnings Per Share (Rs)₹0.67₹6.26₹3.82₹0.99₹0.03
PAT Margin (%)0.839.485.311.950.05
ROE(%)2.0922.2616.504.780.15
ROCE(%)5.8221.9218.8710.336.89
Total Debt/Equity(x)0.350.410.790.780.78

Key Financials

Market Cap : ₹ 217.3 Cr
Revenue (TTM) : ₹ 99.2 Cr
Net Profit(TTM) : ₹ 0.4 Cr
EPS (TTM) : ₹ 0.0
P/E (TTM) : 512.5

Industry Peers & Returns1W1M1Y
VAISHALI PHARMA -1.8% 4.5% 2.6%
SUN PHARMACEUTICAL INDUSTRIES 0.6% -2.1% 16.5%
CIPLA 3.6% 0.2% 2.3%
DR REDDYS LABORATORIES 3% -8.4% 0%
ZYDUS LIFESCIENCES 3.2% -1% 27.4%
DIVIS LABORATORIES 4.3% 6.5% 63.9%
MANKIND PHARMA -2.5% -8% 16.5%
TORRENT PHARMACEUTICALS 2.9% -0.5% 19.4%
LUPIN 8.2% 0.4% 37%


VAISHALI PHARMA Revenues
[NSE : VAISHALI]

Y-o-Y

-8.12 %

5 Yr CAGR

-1.86 %

Years Revenues % Change
Mar2024 ₹70 Cr
-8.12
Mar2023 ₹76 Cr
-100.00
Mar2022 ₹5,377,389 Cr
8,949,387.00
Mar2021 ₹60 Cr
-19.98
Mar2020 ₹75 Cr -


VAISHALI PHARMA Operating Profit
[NSE : VAISHALI]

Y-o-Y

36.21 %

5 Yr CAGR

45.70 %

Years Operating Profit % Change
Mar2024 ₹9.38 Cr
36.21
Mar2023 ₹6.89 Cr
-100.00
Mar2022 ₹264,803 Cr
29,389,784.57
Mar2021 ₹0.90 Cr
-56.70
Mar2020 ₹2.08 Cr -

Operating Margins
Y-o-Y

48.24 %

5 Yr CAGR

48.47 %

Years Operating Margin% % Change
Mar2024 13.46%
48.24
Mar2023 9.08%
84.55
Mar2022 4.92%
228.00
Mar2021 1.5%
-45.85
Mar2020 2.77% -

VAISHALI PHARMA Profit After Tax
[NSE : VAISHALI]

Y-o-Y

64.12 %

5 Yr CAGR

74.39 %

Years Profit After Tax % Change
Mar2024 ₹6.60 Cr
64.12
Mar2023 ₹4.02 Cr
-100.00
Mar2022 ₹104,626 Cr
317,047,384.85
Mar2021 ₹0.03 Cr
-95.38
Mar2020 ₹0.71 Cr -

PAT Margins
Y-o-Y

-91.24 %

5 Yr CAGR

101.85 %

Years PAT Margin(%) % Change
Mar2024 0.83 %
-91.24
Mar2023 9.48 %
78.53
Mar2022 5.31 %
172.31
Mar2021 1.95 %
3,800.00
Mar2020 0.05 % -

VAISHALI PHARMA Earnings Per Share (EPS)
[NSE : VAISHALI]

Y-o-Y

-89.30 %

5 Yr CAGR

117.39 %

Years EPS % Change
Mar2024 ₹0.67
-89.30
Mar2023 ₹6.26
63.87
Mar2022 ₹3.82
285.86
Mar2021 ₹0.99
3,200.00
Mar2020 ₹0.03 -

VAISHALI PHARMA Return on Capital Employed (ROCE)
[NSE : VAISHALI]

Y-o-Y

-73.45 %

5 Yr CAGR

-4.13 %

Years ROCE % Change
Mar2024 5.82%
-73.45
Mar2023 21.92%
16.16
Mar2022 18.87%
82.67
Mar2021 10.33%
49.93
Mar2020 6.89% -

VAISHALI PHARMA Share Price vs Sensex

Current Share Price : ₹16.7
Current MarketCap: ₹ 217.3 Cr
Updated EOD on :Feb 07,2025

Share Price Returns(%) 1 Week 1 Month 1 Year
VAISHALI PHARMA

-1.8%

4.5%

2.6%

SENSEX

0.5%

0.3%

7.9%

VAISHALI PHARMA related INDICES

No BSE index found!
No NSE index found

You may also like the below Video Courses


FAQ about VAISHALI PHARMA Financials


How the annual revenues of VAISHALI PHARMA have changed ?

The Revenues of VAISHALI PHARMA have decreased by -8.12% YoY .

How the Earnings per Share (EPS) of VAISHALI PHARMA have changed?

The Earnings Per Share (EPS) of VAISHALI PHARMA has decreased by -89.30 % YoY .